Low pH formulation of whole IgG antivenom: Impact on quality, safety, neutralizing potency and viral inactivation

Biologicals

Volumn 40, Issue 2, 2012, Pages 129-133

  Solano, Silvia ^a   Segura, Álvaro ^a   León, Guillermo ^a   Gutiérrez, José María ^a   Burnouf, Thierry ^b  

^a UNIVERSIDAD DE COSTA RICA   (Costa Rica)

^b HUMAN PROTEIN PROCESS SCIENCES   (France)

Author keywords

Antivenom; Inactivation; Low pH; Virus

Indexed keywords

IMMUNOGLOBULIN; IMMUNOGLOBULIN G; OCTANOIC ACID; SORBITOL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ARTICLE; CELL AGGREGATION; CONTROLLED STUDY; DRUG FORMULATION; DRUG POTENCY; DRUG PURIFICATION; DRUG QUALITY; DRUG SAFETY; DRUG STABILITY; DRUG STORAGE; ENZYME KINETICS; HERPES SIMPLEX VIRUS 1; IMMUNOGLOBULIN AGGREGATE; IN VIVO STUDY; LETHAL DOSE; MOUSE; NONHUMAN; PH MEASUREMENT; PHYSICAL CHEMISTRY; POLIOMYELITIS VIRUS; PRIORITY JOURNAL; SNAKEBITE; VIRUS INACTIVATION; VIRUS NEUTRALIZATION;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIVENINS; CHEMISTRY, PHARMACEUTICAL; HUMANS; HYDROGEN-ION CONCENTRATION; IMMUNOGLOBULIN G; MICE; QUALITY CONTROL; SAFETY; VIRUS INACTIVATION;

EQUIDAE; HUMAN HERPESVIRUS 1; HUMAN POLIOVIRUS 3; MUS; VIPERIDAE;

EID: 84858069341     PISSN: 10451056     EISSN: 10958320     Source Type: Journal    
DOI: 10.1016/j.biologicals.2011.11.006     Document Type: Article

References (36)

1. Stiehm E.R., Keller M.A., Vyas G.N. Preparation and use of therapeutic antibodies primarily of human origin. Biologicals 2008, 36:363-374.
2. Burnouf T. Recombinant plasma proteins. Vox Sang 2011, 100:68-83.
3. Kivity S., Katz U., Daniel N., Nussinovitch U., Papageorgiou N., Shoenfeld Y. Evidence for the use of intravenous immunoglobulins-a review of the literature. Clin Rev Allergy Immunol 2010, 38:201-269.
4. Lesterhuis W.J., Haanen J.B., Punt C.J. Cancer immunotherapy-revisited. Nat Rev Drug Discov 2011, 10:591-600.
5. Gutierrez J.M., Leon G., Burnouf T. Antivenoms for the treatment of snakebite envenomings: the road ahead. Biologicals 2011, 39:129-142.
6. Chippaux J.P., Goyffon M. Venoms, antivenoms and immunotherapy. Toxicon 1998, 36:823-846.
7. Theakston R.D., Warrell D.A., Griffiths E. Report of a WHO workshop on the standardization and control of antivenoms. Toxicon 2003, 41:541-557.
8. Kasturiratne A., Wickremasinghe A.R., de Silva N., Gunawardena N.K., Pathmeswaran A., Premaratna R., et al. The global burden of snakebite: a literature analysis and modelling based on regional estimates of envenoming and deaths. PLoS Med 2008, 5:e218.
9. WHO WHO guidelines for the production, control and regulation of snake antivenom immunoglobulins 2010, World Health Organization, Geneva.
10. Gutierrez J.M., Theakston R.D., Warrell D.A. Confronting the neglected problem of snake bite envenoming: the need for a global partnership. PLoS Med 2006, 3:e150.
11. Grandgeorge M., Véron J.L., Lutsch C., Makula M.F., Riffard P., Pépin S., et al. Preparation of improved F(ab')2 antivenoms. An example: new polyvalent European viper antivenom (equine). Envenomings and their treatments 1996, 161-172. Fondation Marcel Mérieux, Lyon. C. Bon, M. Goyffon (Eds.).
12. Denton A. Practical experience with the use of Planova 15N in the manufacture of FDA approved products. 7th Planova workshop 2004 in Europe 2004, Asahi kasei, Lisbon, Portugal.
13. Burnouf T., Radosevich M., Goubran H.A., Willkommen H. Place of nanofiltration for assuring viral safety of biologicals. Curr Nanoscience 2005, 1:189-201.
14. Burnouf T., Griffiths E., Padilla A., Seddik S., Stephano M.A., Gutierrez J.M. Assessment of the viral safety of antivenoms fractionated from equine plasma. Biologicals 2004, 32:115-128.
15. Radosevich M., Burnouf T. Intravenous immunoglobulin G: trends in production methods, quality control and quality assurance. Vox Sang 2010, 98:12-28.
16. Rojas G., Jimenez J.M., Gutierrez J.M. Caprylic acid fractionation of hyperimmune horse plasma: description of a simple procedure for antivenom production. Toxicon 1994, 32:351-363.
17. Angulo Y., Estrada R., Gutierrez J.M. Clinical and laboratory alterations in horses during immunization with snake venoms for the production of polyvalent (Crotalinae) antivenom. Toxicon 1997, 35:81-90.
18. Segura A., Leon G., Su C.Y., Gutierrez J.M., Burnouf T. Assessment of the impact of solvent/detergent treatment on the quality and potency of a whole IgG equine antivenom. Biologicals 2009, 37:306-312.
19. Gutiérrez J.M., Rojas G., Lomonte B., Gene J.A., Chaves F., Alvarado J., et al. Standardization of assays for testing the neutralizing ability of antivenoms. Toxicon 1990, 28:1127-1129. author reply 9-32.
20. Cuthbertson B., Perry R.J., Foster P.R., Reid K.G., Crawford R.J., Yap P.L. The viral safety of intravenous immunoglobulin. J Infect 1987, 15:125-133.
21. WHO Guidelines on viral inactivation and removal procedures intended to assure the viral safety of human blood plasma products 2003, Geneva. http://www.WHO.int/bloodproducts.
22. Burnouf T. Modern plasma fractionation. Transfus Med Rev 2007, 21:101-117.
23. Burnouf T., Radosevich M. Reducing the risk of infection from plasma products: specific preventative strategies. Blood Rev 2000, 14:94-110.
24. McCue J.P., Hein R.H., Tenold R. Three generations of immunoglobulin G preparations for clinical use. Rev Infect Dis 1986, 8(Suppl 4):S374-S381.
25. Hooper J.A. Intravenous immunoglobulins: evolution of commercial IVIG preparations. Immunol Allergy Clin North Am 2008, 28:765-778. viii.
26. Schiff R.I. Intravenous gammaglobulin: pharmacology, clinical uses and mechanisms of action. Pediatr Allergy Immunol 1994, 5:63-87.
27. Omar A., Kempf C., Immelmann A., Rentsch M., Morgenthaler J.J. Virus inactivation by pepsin treatment at pH 4 of IgG solutions: factors affecting the rate of virus inactivation. Transfusion 1996, 36:866-872.
28. Biesert L. Virus validation studies of immunoglobulin preparations. Clin Exp Rheumatol 1996, 14(Suppl. 15):S47-S52.
29. Reid K.G., Cuthbertson B., Jones A.D., McIntosh R.V. Potential contribution of mild pepsin treatment at pH4 to the viral safety of human immunoglobulin products. Vox Sang 1988, 55:75-80.
30. Bos O.J., Sunye D.G., Nieuweboer C.E., van Engelenburg F.A., Schuitemaker H., Over J. Virus validation of pH 4-treated human immunoglobulin products produced by the Cohn fractionation process. Biologicals 1998, 26:267-276.
31. Louie R.E., Galloway C.J., Dumas M.L., Wong M.F., Mitra G. Inactivation of hepatitis C virus in low pH intravenous immunoglobulin. Biologicals 1994, 22:13-19.
32. Poelsler G., Berting A., Kindermann J., Spruth M., Hammerle T., Teschner W., et al. A new liquid intravenous immunoglobulin with three dedicated virus reduction steps: virus and prion reduction capacity. Vox Sang 2008, 94:184-192.
33. Lazar A., Epstein E., Lustig S., Barnea A., Silberstein L., Reuveny S. Inactivation of West-Nile virus during peptic cleavage of horse plasma IgG. Biologicals 2002, 30:163-165.
34. Burnouf T., Terpstra F., Habib G., Seddik S. Assessment of viral inactivation during pH 3.3 pepsin digestion and caprylic acid treatment of antivenoms. Biologicals 2007, 35:329-334.
35. Dichtelmuller H., Rudnick D., Kloft M. Inactivation of lipid enveloped viruses by octanoic acid treatment of immunoglobulin solution. Biologicals 2002, 30:135-142.
36. Korneyeva M., Hotta J., Lebing W., Rosenthal R.S., Franks L., Petteway S.R. Enveloped virus inactivation by caprylate: a robust alternative to solvent-detergent treatment in plasma derived intermediates. Biologicals 2002, 30:153-162.